In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other high-yield dividend stocks. Dividend stocks have been investors’ favorites for a long ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer patient ...

Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

As Leo stands in his office, overseeing the entrance of Viatris' bustling office in the Netherlands, he reflects on the 50 years that have shaped his journey with the company. From his early days ...

Shares of Viatris Inc. VTRS shed 0.33% to $11.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 ...

Shares of Viatris Inc. VTRS dropped 0.68% to $11.72 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...